We provide the latest news
from the world of economics and finance
(RTTNews) - Dermatology therapeutics company, Verrica Pharmaceuticals Inc. (VRCA), Monday announced that it had filed a lawsuit, alleging Dormer Laboratories Inc., a Canada-based pharmaceutical lab, of false and misleading advertising, and promotion of unapproved cantharidin-containing drugs in the U.S. market.
According to the lawsuit filed in the Eastern District of Pennsylvania, YCANTH is the only cantharidin-containing drug approved by the FDA for the treatment of molluscum contagiosum, a highly contagious skin disease, especially in children.
Verrica said that it had requested the court to prohibit Dormer Labs from marketing, selling, and distributing unapproved drugs in the U.S.
The pharmaceutical company also sought compensatory, statutory, and punitive damages from Dormer Labs for the violation of the federal Lanham Act and Pennsylvania law.
In the pre-market activity, Verrica Pharmaceuticals is climbing 0.71 percent, to $5.71 on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.